OncoMed Pharmaceuticals (NASDAQ: OMED) is expanding the responsibilities of its president, John Lewicki, to include chief executive. Lewicki was appointed president of the Redwood City, CA, cancer drug developer in January. With his promotion to CEO, Lewicki also joins OncoMed’s board of directors. Lewicki came to OncoMed in 2004 as senior vice president of research and development and moved to other roles in the company in subsequent years. Last year, OncoMed’s two lead drugs failed in clinical trials. The company’s pipeline currently holds six clinical-stage compounds.